Top

Published in:

01-08-2005 | Letter to the Editor

Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab

Authors: S. Vallet, A. Tempescul, A. Tran, M. C. Legrand-Quillien, V. Narbonne, C. Berthou

Published in: Annals of Hematology | Issue 8/2005

Excerpt

Rituximab is a chimeric human/mouse monoclonal antibody directed against the CD20 antigen. It has become part of the standard therapy for non-Hodgkin’s lymphoma (NHL). Rituximab effectively kills lymphoma B cells and rapidly leads to the sustained depletion of peripheral blood B cells. Mantle cell lymphoma (MCL) is incurable with standard therapy. The median survival time is short (43 months). Rituximab has been shown to trigger a response in between 20 and 38% of patients with MCL [1]. …

Boye J, Elter T, Engert A (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520–535

Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A (2000) Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894–895

Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000CrossRef

Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, Imrit K, Preti RA (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486–1488

Quartier P, Tournilhac O, Archimbaud C, Lazaro L, Chaleteix C, Millet P, Peigue-Lafeuille H, Blanche S, Fischer A, Casanova JL, Travade P, Tardieu M (2003) Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 36:e47–e49

Hernandez JA, Diloy R, Salat D, del Rio N, Martinez X, Castellvi JM (2003) Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica 88:ECR22

Song KW, Mollee P, Patterson B, Brien W, Crump M (2002) Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 119:125–127

Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S, Asaka M, Imamura M, Masauzi N (2004) Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin’s lymphoma. Ann Hematol 83:58–60

Flohr T, Hess GR, Kreiter S, Meyer RG, Huber C, Derigs G (2000) Immune reconstitution after autologous CD34-positive selected peripheral blood stem cell transplantation combined with rituximab for refractory B-cell non-Hodgkin’s lymphoma. Blood 96:709a (abstract)

10.

Horwitz SM, Breslin S, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor T, Brown BW, Blume KG, Horning SJ (2000) Adjuvant rituximab after autologous peripheral blood stem cell transplant results in delayed immune reconstitution with increase in infectious complications. Blood 96:707a (abstract)

11.

McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833PubMed

Title: Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab
Authors: S. Vallet
A. Tempescul
A. Tran
M. C. Legrand-Quillien
V. Narbonne
C. Berthou
Publication date: 01-08-2005
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 8/2005
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-005-1038-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Cytomegalovirus-associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2005

Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab

Anti-CD20 antibody (Rituximab) therapy in a myasthenia gravis patient with follicular lymphoma

Spontaneous rupture of the spleen in a patient with B-cell acute lymphoblastic leukaemia

Chronic myeloid leukemia: a model for oncology

Analysis of leukocyte binding to depletion filters: role of passive binding, interaction with platelets, and plasma components

An unusual presenting feature of precursor T-cell acute lymphoblastic leukemia/lymphoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page